Collagen Solutions PLC Director/PDMR Shareholding (0995K)
06 April 2018 - 6:31PM
UK Regulatory
TIDMCOS
RNS Number : 0995K
Collagen Solutions PLC
06 April 2018
Collagen Solutions Plc
(the "Company")
6 April 2018
Director / PDMR Dealing
The Company today announces that on 5 April 2018, Hilary Spence,
Chief Financial Officer ("CFO") of the Company, was granted options
(the "Options") over 2,000,000 ordinary shares of 1 pence each in
the share capital of the Company ("Shares") exercisable at a price
of 2.70 pence per Share.
The Options, will vest in three equal tranches on the first,
second and third anniversaries of 3 January 2018, being the date of
Ms. Spence's appointment as CFO. Such vesting will be conditional
on her continued employment. In addition, the ability to exercise
any vested Options will be dependent on achieving a closing middle
market price per Share of 10 pence at any time after the date of
grant and on the Company delivering sustainable positive cash flows
from operations for any period of six months. All Options will
lapse after 10 years from the date of grant, being 5 April
2018.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and
persons closely associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ------------------------------------------------------------
a) Name Hilary Spence
--- --------------------------- -------------------------------
2 Reason for the
notification
--- --------------------------- -------------------------------
a) Position/status Chief Financial Officer
--- --------------------------- -------------------------------
b) Initial notification Initial Notification
/Amendment
--- --------------------------- -------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ------------------------------------------------------------
a) Name Collagen Solutions Plc
--- --------------------------- -------------------------------
b) LEI 213800IFY1CVGRGETL95
--- --------------------------- -------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ------------------------------------------------------------
a) Description of Ordinary shares of 1p each
the financial instrument,
type of instrument
ISIN Code: GB00B94T6Y14
Identification
code
--- --------------------------- -------------------------------
b) Nature of the transaction Grant of options over ordinary
shares of 1p each exercisable
at 2.70p per share
--- --------------------------- -------------------------------
c) Price(s) and volume(s)
Price(s): Volume(s):
2.70 pence 2,000,000
--- --------------------------- -------------------------------
Aggregated information
* Aggregated volume N/A
N/A
* Price
--- --------------------------- -------------------------------
e) Date of the transaction 05/04/2018
--- --------------------------- -------------------------------
f) Place of the transaction Outside a trading venue
--- --------------------------- -------------------------------
For further information please contact:
Collagen Solutions Plc Tel: +44 (0) 141 648 9100
Jamal Rushdy, Chief Executive Officer
Hilary Spence, Chief Financial Officer
Lisa Baderoon, Head of Investor Relations Tel: +44 (0) 7721 413 496 or lisa.baderoon@collagensolutions.com
Cenkos Securities plc (NOMAD and Broker) Tel: +44 (0) 207 397 8900
Stephen Keys
Steve Cox
Walbrook PR Tel: +44 (0) 20 7933 8780 or collagen@walbrookpr.com
Anna Dunphy Mob: +44 (0) 7876 741 001
Helen Cresswell
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHFKADBFBKKFQK
(END) Dow Jones Newswires
April 06, 2018 04:31 ET (08:31 GMT)
Collagen Solutions (LSE:COS)
Historical Stock Chart
From Apr 2024 to May 2024
Collagen Solutions (LSE:COS)
Historical Stock Chart
From May 2023 to May 2024